Research & KnowledgeEvent: September 8, 2026
GSK accelerated research programmes are looking to target multiple inflammatory pathways, including TSLP and IL-33, to build a diverse portfolio for COPD patients.
Published
Signal category
Research & Knowledge
Quote
“Our accelerated research programmes are looking at ways to target multiple inflammatory pathways, including TSLP and IL-33, with the goal of building a portfolio as diverse as people living with COPD”
— GSK team
Company
- Industry
- Pharmaceutical Manufacturing
- Location
- London, GB
- Company size
- 91,880 employees
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia